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Table 1: Baseline characteristics and outcomes for 171 HIV-infected patients receiving ART and 
either rifabutin of rifampicin for treatment of tuberculosis. 
 
                                                                   Groups 
                                                                                                          
 
Variable 
Rifabutin  
N=41 
% (n) 
Rifampicin  
N=130
% (n) 
p valuea 
Baseline    
Age Median [IQR], years 37.0  
[32.4, 43.0] 
35.9  
[32.0, 43.0] 
0.553* 
Sex Female 34.1 (14) 43.8 (57)  0.272 
Male 65.9 (27) 56.2 (73)  
Ethnic origin White 39.0 (16) 23.1 (30) 0.003 
Black 41.5 (17) 70.0 (91)  
Other 19.5 (8) 6.9 (9)  
HIV transmission Homosexual 36.6 (15) 19.2 (25) 0.051 
Heterosexual 53.7 (22) 73.1 (95)  
IVDU 9.8 (4) 7.7 (10)  
Hospital attended Chelsea & Westminster 63.4 (26) 50.8 (66)  0.031 
University College 
London 
36.6 (15) 49.2 (64)   
Type of ART NNRTI 22.0 (9) 100.0 (130) - 
PI 78.0 (32) 0.0 (0)  
Had TB in the past No 92.7 (38) 90.0 (117) 0.764** 
Yes  7.3 (3) 10.0 (13)  
Type of TB Diagnosis  Confirmed  82.9 (34) 79.2 (103) 0.605 
Presumptive 17.1 (7) 20.8 (27)  
Time between HIV & TB 
diagnosis 
Median [IQR], months 58 [3,108] 8 [0,54] 0.001* 
Site of TB  Pulmonary 70.7 (29) 73.1 (95) 0.878** 
 Lymph node 19.5 (8)  16.2 (21)  
 Disseminated 9.8 (4) 10.8 (14)  
Outcomes of treatment    
Duration of TB treatment Median [IQR], months 6 [6,9] 6 [6,9] 0.634* 
Completed TB regimen Yes 87.8 (36) 96.9 (126)  0.037** 
 No 12.2 (5) 3.1 (4)  
TB Treatment Interruption Yes   25.0 (10)  17.7 (23)  0.307 
No  75.0 (30)b 82.3 (107)  
IRIS  Yes  29.3 (12) 12.3 (16) 0.012 
No 70.7 (29) 87.6 (112)c  
Change in CD4 count at end 
of TB treatment  
Median [IQR], cells/mm3 75 
[-12,241] 
70 
[8,170] 
0.781* 
HIV VL at end of TB 
treatment  
Undetectable 87.5 (35) 78.6 (99) 0.256** 
Detectable 12.5 (5) 21.4 (27)d  
Died by end of treatment Yes  2.4 (1) 2.3 (3) 1.000** 
 
Key: a 2 test unless specified: *Mann-Whitney U test: ** Fisher’s exact test: b outcome not recorded 
for one patient:  c outcome not recorded for two patients:   d plasma HIV viral load result not available 
for one patient: IQR =interquartile range: IVDU =injecting drug user: ART =antiretroviral therapy: 
NNRTI =non-nucleoside reverse transciptase inhibitor: PI =protese inhibitor: IRIS =immune 
reconstitution inflammatory syndrome: VL =plasma HIV viral load. 
